**SUPPORTING INFORMATION**

**Exclusion Criteria**

Patients with any of the following criteria were excluded from the study:

* Type 1 diabetes
* Proliferative diabetic retinopathy
* Treatment with insulin <12 weeks before enrollment
* History of clinically significant renal disease (e.g., renovascular occlusive disease, nephrectomy, or renal transplant), significant dysuria caused by neurogenic bladder or benign prostatic hypertrophy, for example; urinary tract infection or genital infection
* Chronic disease requiring continuous use of systemic corticosteroids, immunosuppressants, or loop diuretics
* History of cerebrovascular attack, unstable angina, myocardial infarction, angioplasty, or serious cardiac diseases (New York Heart Association class III–IV) <12 weeks before enrollment
* Serious cardiovascular or cerebrovascular disease that might affect the administration of the study drugs or safety assessments
* Uncontrollable psychiatric disorder
* Pregnant females
* Females wishing to become pregnant or unwilling to use appropriate contraception
* Males unwilling to use appropriate contraception
* Severe trauma, severe infection, or perioperative stage
* History of drug addiction or alcohol abuse
* Malignant tumor, benign pheochromocytoma or a history of malignant tumor or benign pheochromocytoma (except patients who had not received treatment for ≥5 years or were unlikely to have recurrence)
* Known or suspected hypersensitivity to ipragliflozin or other SGLT2 inhibitors
* Prior treatment with ipragliflozin; prior or current participation in another clinical study, post-marketing study or medical device study <12 weeks before enrollment
* Inability or unwillingness to adhere to the study protocol
* Serum creatinine exceeding the upper limit of normal (ULN)
* Urinary microalbumin/creatinine ratio >300 mg/g
* Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2
* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 times the ULN, or total bilirubin level >2 times the ULN
* Uncontrollable severe hypertension (systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg)
* Severe gastrointestinal disease or a history of surgery for serious gastrointestinal disease
* Presence or history of diabetic ketoacidosis or lactic acidosis
* Current hepatitis or a carrier of hepatitis B surface antigen, hepatitis C virus antibody, or known to be positive for human immunodeficiency virus (HIV) -1 and/or HIV-2
* Patients with a clinical condition which, in the opinion of the investigator, would not allow safe conduct of the study